This is a Phase 1, open-label, multicenter, dose-escalation, safety, tolerability, pharmacokinetic and pharmacodynamic study with cohort expansion at the RP2D to evaluate safety and anti- tumor activity of Q702 administered orally.
Drug: Q702
The study drug Q702 will be administered once daily by mouth on Days 1 through 7 and Days 15 through 21 of every treatment cycle.
Inclusion Criteria:
- Patients with histologically or cytologically confirmed advanced or metastatic solid
tumors, that have progressed following standard of care therapy or for which there is
no standard therapy which confers clinical benefit
- Measurable disease per RECIST v 1.1
- ECOG performance status 0 or 1
- Life expectancy of at least 3 months
- Age ≥ 18 years
- Signed, written IRB-approved informed consent form
Exclusion Criteria:
- New York Heart Association Class III or IV cardiac disease, or myocardial infarction,
severe unstable angina, coronary/peripheral artery bypass graft, congestive heart
failure within the past 6 months
- Have a corrected QT interval (using Fridericia's correction formula) (QTcF) of >470
msec (females) and >450 msec (males)
- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic
therapy
- Active, poorly controlled autoimmune or inflammatory diseases
University of Southern California
Los Angeles, California, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
Northwestern University
Chicago, Illinois, United States
Atlantic Health System Hospital
Morristown, New Jersey, United States
Qurient Clinical Trial Information
+82-31-8060-1610 - (KST)
clinicaltrial_info@qurient.com